Home›Clinical trials›A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individua

A study listed on ClinicalTrials.gov.

Recruiting now. Registry record last updated February 27, 2026.

Who can join
Adults 18 to 59, BMI 20+.
What you take
Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts
The study runs about 6 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor Athletic Greens InternationalDrug investigational drugClass OtherSites 1 USEnrollment target 120

What this study is for

Primary condition: Nutrition Intake. Also studied in: Nutrition Status, Gastrointestinal Microbiome, GLP-1.

Full scientific study title: A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individua.

Who can join

Age18 to 59SexAnyBMI20 to 31.9

Adults 18 to 59, BMI 20+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Be male or female
  • Be aged 18-59.
  • Has a BMI between 20-31.9.
  • Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)
  • Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours.

Key exclusion criteria

  • Anyone with a diagnosis of Type I or Type II diabetes.
  • Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.
  • Anyone who has taken any multivitamin/multimineral supplements within the past 3 months.
  • Anyone who has taken a probiotic supplement within the past month.
  • Anyone who has regularly consumed (5 days/week or more) products that target healthy aging, anti-aging, longevity, gut health, energy, or ingestive behaviour (such as cravings), including resveratrol, quercetin, pterostilbene, coQ10, grapefruit, nicotinamide riboside, prebiotic fiber, green tea, niacin (vitamin B3) within the past 2 months.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

California1 site

Timeline

Started enrolling: February 2026. Expected completion: August 2026. Last updated on ClinicalTrials.gov: February 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.